For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Vyndamax and Attruby represents a genuine change. These groundbreaking therapies preserve the transthyretin protein, slowing its harmful build-up and lessening the impact of the disease . Patients are now experiencing benefits in their